Last $2.26 USD
Change Today -0.09 / -3.83%
Volume 80.3K
BPTH On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

bio-path holdings inc (BPTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/7/14 - $4.50
52 Week Low
08/11/14 - $1.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIO-PATH HOLDINGS INC (BPTH)

Related News

No related news articles were found.

bio-path holdings inc (BPTH) Related Businessweek News

No Related Businessweek News Found

bio-path holdings inc (BPTH) Details

Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase I study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.

2 Employees
Last Reported Date: 03/31/14
Founded in 2007

bio-path holdings inc (BPTH) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $375.0K
Co-Founder and Director
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

bio-path holdings inc (BPTH) Key Developments

Bio-Path Holdings, Inc. to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma

Bio-Path Holdings, Inc. announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma. Bio-Path has a completed preclinical package of toxicity, tissue distribution, pharmacokinetics and efficacy studies. The company plans to file an Investigational New Drug application (IND) in the first half of 2015. Liposomal Bcl-2 (“L-Bcl-2”) is a liposomal encapsulated oligonucleotide targeted to the translation initiation site of human Bcl-2 mRNA. The antisense oligonucleotide in L-Bcl-2 used by Bio-Path Holdings is a nuclease-resistant, hydrophobic analog of phosphodiesters containing the company’s proprietary P-ethoxy backbone. The main advantage of this structure is the lack of a sulfur moiety, which has been associated with bleeding diathesis. Bcl-2 over expression has been associated with up to 60% of cancers. Bio-Path’s L-Bcl-2 demonstrated excellent toxicity and efficacy in preclinical studies. The in vivo studies of follicular lymphoma in SCID mice demonstrated a 60% survival rate, with the treated mice remaining alive while continuing to receive on-going treatment with the compound. The company expects that the Phase I clinical trial design will use a standard 3+3 dose escalation design, with 50% dose scalation with each round. The company anticipates that the favorable toxicity profile of its lead drug candidate Liposomal Grb-2, currently in clinical trials, will allow it to start this Phase I clinical trial at a higher dose. On this basis, the Company is planning a Phase I clinical trial for Liposomal Bcl-2 that will require five cohorts and only 15 patients.

Bio-Path Holdings, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:30 PM

Bio-Path Holdings, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Peter H. Nielsen, Co-Founder, Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief Accounting Officer and Treasurer.

Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Cash Flow Results for the Nine Months Ended September 30, 2014

Bio-Path Holdings, Inc. reported earnings results for the third quarter and cash flow results for the nine months ended September 30, 2014. For the quarter, the company reported a net loss of $1,148,409 compared to a net loss of $1,393,207 for the three months ended September 30, 2013. The decrease in the net loss for the three months ended September 30, 2014, compared to the three months ended September 30, 2013, was due to lower research and development and general and administrative expenses. Net loss per share, both basic and diluted, was $0.01 per share for the three months ended September 30, 2014 and $0.02 per share for the three months ended September 30, 2013. Net cash used in operating activities for the first nine months of 2014 was $2,661,479 compared to $1,836,311 for the first nine months of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BPTH:US $2.26 USD -0.09

BPTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BPTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation BPTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-PATH HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at